Table 1.
Patient Characteristics (N=55)
| Characteristic | Value |
|---|---|
| Age, y | 71.1±11.8 |
| BMI | 25.3±3.6 |
| Men, n (%) | 42 (76.4) |
| Clinical presentation | |
| Stable angina pectoris, n (%) | 46 (83.6) |
| STEMI, n (%) | 3 (5.5) |
| NSTE‐ACS, n (%) | 6 (10.9) |
| Prior MI, n (%) | 5 (9.1) |
| Prior PCI, n (%) | 17 (30.9) |
| Prior CABG, n (%) | 0 (0.0) |
| Hypertension, n (%) | 46 (83.6) |
| Dyslipidemia, n (%) | 46 (83.6) |
| Diabetes, n (%) | 19 (34.5) |
| Treatment of diabetes, n (% in patients with diabetes) | |
| Diet | 8 (42.1) |
| Oral medication | 10 (52.6) |
| Oral medication and insulin | 1 (5.3) |
| Renal insufficiency, n (%) | 15 (27.3) |
| Family history of CAD, n (%) | 2 (3.6) |
| Smoking | |
| Current smoker, n (%) | 8 (14.5) |
| Past smoker, n (%) | 28 (50.9) |
| Never smoker, n (%) | 19 (34.5) |
| Creatinine, mg/dL | 0.93±0.26 |
| Total cholesterol, mg/dL | 182.3±34.8 |
| Low‐density lipoprotein cholesterol, mg/dL | 104.6±27.0 |
| High‐density lipoprotein cholesterol, mg/dL | 52.2±14.6 |
| Triglycerides, mg/dL | 125.0 (84.0–163.0) |
| HbA1c, % | 6.1 (5.7–6.6) |
| WBC, count/μL | 6771±1997 |
| Hemoglobin, g/dL | 13.8±1.6 |
| Hematocrit, % | 40.5±4.2 |
| Platelets, 103/μL | 215.2±66.1 |
| hs‐CRP, mg/dL | 0.09 (0.05–0.12) |
| BNP, pg/mL | 16.2 (9.6–53.9) |
| LVEF, % | 63.4 (58.0–66.0) |
| Medication at admission | |
| Aspirin, n (%) | 37 (67.3) |
| P2Y12 inhibitor, n (%) | 33 (60.0) |
| Warfarin, n (%) | 0 (0.0) |
| DOAC, n (%) | 6 (10.9) |
| Statin, n (%) | 36 (65.5) |
| PCSK9 inhibitor, n (%) | 0 (0.0) |
| β‐Blocker, n (%) | 12 (21.8) |
| ACEI/ARB, n (%) | 28 (50.9) |
| Antibiotic, n (%) | 0 (0.0) |
| Culprit vessel | |
| LAD, n (%) | 39 (70.9) |
| LCX, n (%) | 8 (14.5) |
| RCA, n (%) | 8 (14.5) |
Values are mean±SD, n (%), or median (interquartile range). ACEI/ARB indicates angiotensin‐converting enzyme inhibitor/angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; BNP, B‐type natriuretic peptide; CAD, coronary artery disease; DOAC, direct oral anticoagulant; HbA1c, glycosylated hemoglobin; hs‐CRP, high‐sensitivity C‐reactive protein; LAD, left anterior descending artery; LCX, left circumflex artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction, NSTE‐ACS, non–ST‐segment–elevation acute coronary syndrome; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase subtilisin/kexin type 9; RCA, right coronary artery; STEMI, ST‐segment–elevation myocardial infarction; and WBC, white blood cell.